HIV-1 acquired drug resistance to integrase inhibitors in a cohort of antiretroviral therapy multi-experienced Mexican patients failing to raltegravir: a cross-sectional study.
High prevalence of integrase mutation L74I in West African HIV-1 subtypes prior to integrase inhibitor treatment.
PMID: 32105319
2020
The Journal of antimicrobial chemotherapy
Result: Four had T97A [this was the consensus in three of them and a minority variant in one (who also had L74I)], another participant had an E138K minority variant and another had a G140A minority variant.
Characterization of HIV-1 Integrase Gene and Resistance Associated Mutations Prior to Roll out of Integrase Inhibitors by Kenyan National HIV-Treatment Program in Kenya.
PMID: 32116431
2020
Ethiopian journal of health sciences
Abstract: However, polymorphic accessory mutations associated with reduced susceptibility of integrase inhibitors were observed in low frequency; M50I (12.2%), T97A (3.7%), S153YG, E92G (1.6%), G140S/A/C (1.1%) and E157Q (0.5%).
Result: These mutations were M50I (12.2%), T97A (3.7%), S153YG, E92G (1.6%), G140S/A/C (1.1%) and E157Q (0.5%).
Table: T97A
Circulating HIV-1 Integrase Genotypes in Tanzania: Implication on the Introduction of Integrase Inhibitors-Based Antiretroviral Therapy Regimen.
PMID: 32126792
2020
AIDS research and human retroviruses
Abstract: No major INSTI resistance mutations were found; however, accessory resistance mutations at positions T97A, E157Q, G163E/K, and 128A/T were detected in 5% of subjects.
Genetic Features of HIV-1 Integrase Sub-Subtype A6 Predominant in Russia and Predicted Susceptibility to INSTIs.
Introduction: In vitro selection experiments indicated that substitutions in the 74 position combined with major mutations (G140A/C/S, Q148 H/K/R) and other accessory mutations (V75I, T97A) can significantly reduce susceptibility to INSTI, whereas this mutation alone has minimal impact on INSTI susceptibility or HIV-1 replication capacity.
Result: Additionally, 3 INSTI-naive patients had accessory mutations: E157Q (2/183; 1.1%) and T97A (1/183; 0.5%), which alone have minimal impact on INSTI susceptibility or HIV-1 replication capacity.
Prevalence of HIV-1 Integrase Strand Transfer Inhibitor Resistance in Treatment-Naive Voluntary Counselling and Testing Clients by Population Sequencing and Illumina Next-Generation Sequencing in Taiwan.
Drug Resistance Mutations Against Protease, Reverse Transcriptase and Integrase Inhibitors in People Living With HIV-1 Receiving Boosted Protease Inhibitors in South Africa.
Abstract: Among the InSTI major RAM two (2.2%) sequences have Y143R and T97A mutations while one sample had T66I.
Result: Two (2%) patient had a viral sequences with Y143R major InSTI mutation in combination with the accessory T97A mutation, which confers high-level resistance to raltegravir (RAL), intermediate resistance to elvitegravir (EVG), and
Discussion: We confirmed Y143R in our study and this mutation in combination with T97A also impaired EVG susceptibility and showed possible low-level resistance.
Discussion: We observed the presence of Y143R in combination with T97A in one of our patients receiving ABC, 3TC, LPV/r.
Absence of Integrase Inhibitor-Associated Resistance Among Antiretroviral Therapy-Naive HIV-1-Infected Adults in Guangdong Province, China, in 2018.
Abstract: Among them, no major resistance mutations to INSTIs were identified, and four accessory mutations, including T97A (0.12%, 1/827), Conclusion: In conclusion, our results demonstrate that drug resistance mutations associated with INSTIs, including T97A, A128T, E157Q, and G163R, were detected among ART-naive HIV-1-infected adults in Guangdong, China, in 2018.
Result: The mutations were T97A (0.12%, 1/827), A128T (0.24%, 2/827), E157Q (0.85%, 7/827), and G163R (0.24%, 2/827).
Table: T97A
Susceptibility to HIV-1 integrase strand transfer inhibitors (INSTIs) in highly treatment-experienced patients who failed an INSTI-based regimen.
PMID: 32450199
2020
International journal of antimicrobial agents
Abstract: Two isolates contained L74M, E138K, G140S and Q148H, or L74M, T97A, S119T, E138K, G140S, Y143R and Q148H, and had high-level resistance to all INSTIs, including BIC and DTG.
Molecular dynamic simulations to investigate the structural impact of known drug resistance mutations on HIV-1C Integrase-Dolutegravir binding.
Introduction: Genetic resistance pathways including primary mutations at codons Y143C/H/R, Q148H/K/R or N155H together with one or more additional associated secondary mutations at L74M, E92Q, T97A, E138E/A/K or G140S/A, has been reported to result in higher levels of resistance with RAL treatment.
HIV mutation literature information.
PMID: 
2020
AIDS research and therapy
Browser Board
Co-occurred Entities
Filtrator
ViMRT